Seagen Stockholders Approve Acquisition by Pfizer
Pfizer (NYSE:PFE) Selling $31 Billion Of Bonds In 8 Parts For Seagen Deal - Bloomberg
Shares of biotech company Seagen (NASDAQ:SGEN) declined Tuesday morning, falling by over 6%. Weakness followed a report from Bloomberg overnight that suggested the Federal Trade...
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Entrepreneurship plays a significant role in the US economy as new businesses are a crucial driving force for the country's economic growth. Academic research highlights that...
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
|Average||220.60 (+12.86% Upside)|
|No. of Analysts||20|
|Moving Averages||Strong Buy||Strong Buy||Buy||Buy||Strong Buy|
|Technical Indicators||Strong Buy||Strong Buy||Buy||Buy||Strong Buy|
|Summary||Strong Buy||Strong Buy||Buy||Buy||Strong Buy|